In the past three years, prostate-specific membrane antigen (PSMA) has become a well-established target for imaging and therapy in prostate cancer, and the isotopes 43Sc and 47Sc have been explored for their potential in PSMA-targeted radioligand therapy [52,108]. This evidence concerns the gene FOLH1 and prostate carcinoma.